COVAX Facility

COVAX: Ensuring global equitable access to COVID-19 vaccines

With a fast-moving pandemic, no one is safe, unless
everyone is safe

What is COVAX

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

Why we need COVAX

Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.

PRESS RELEASE

Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility

21 September 2020 – Press release

ARTICLE

COVAX explained

 

3 September 2020 – Article

PRESS RELEASE

172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility

24 August 2020 – Press release

ARTICLE

Call for applications: COVAX seeks civil society representatives to contribute to ensuring equitable global access to COVID-19 vaccines

19 August 2020 – Article

ARTICLE

Why is no one safe until everyone is safe during a pandemic?

 

17 August 2020 – Article

PRESS RELEASE

92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC
 

31 July 2020 – Press release

Act Now. Act Together. Act boldly to end Covid-19.

Important documents

• COVAX Facility Explainer
• WHO COVID-19 vaccine allocation

Why we need to build  manufacturing capacity now

1. Produce early doses to support clinical studies
2. Scale up processes to industrial scale before clinical trials begin
3. Scale-out products in different countries to expand capacity
4. Stockpile vaccines in bulk in anticipation of dose level definition
5. Anticipate projects failing during clinical development
6. Repurpose facilities for successful products, if needed